BioLineRx Ltd.
BLRX
$4.24
-$0.33-7.22%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 260.87% | 45.26% | -1,302.89% | 169.54% | 94.99% |
| Total Depreciation and Amortization | -90.73% | 111.79% | 76.47% | -46.93% | 38.64% |
| Total Amortization of Deferred Charges | -5.39% | -- | -- | -- | -- |
| Total Other Non-Cash Items | -7.14% | -434.71% | 72.29% | -43.64% | -202.22% |
| Change in Net Operating Assets | -25.12% | 88.06% | 52.33% | 33.11% | -173.24% |
| Cash from Operations | 69.91% | 12.37% | 13.28% | 19.70% | -382.69% |
| Capital Expenditure | -- | -- | 100.00% | 15.63% | -100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -173.33% | 9.59% | 218.07% | -151.55% | 182.04% |
| Cash from Investing | -173.29% | 9.65% | 217.70% | -151.81% | 181.82% |
| Total Debt Issued | -- | -- | -100.00% | -- | -- |
| Total Debt Repaid | 89.70% | -1,065.99% | -14.19% | -1.68% | -3.59% |
| Issuance of Common Stock | -2.70% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 952.12% | 8.95% | -105.10% | 2,771.03% | -107.61% |
| Foreign Exchange rate Adjustments | -150.62% | 100.00% | 129.78% | -633.33% | -73.44% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -187.50% | 303.30% | -121.66% | 109.39% | 149.97% |